Nexalin Technology NXL
NASDAQ NXL
$7.53 +3.25 (+75.93%)
As of: Oct 1, 2026 · 3:59 PM EDT

Nexalin Technology (NXL) Current Deferred Revenue (2021)

Updated

Nexalin Technology (NXL) recorded Current Deferred Revenue of $130,000 in Q4 2021.

Analysis

Nexalin Technology (NXL) Current Deferred Revenue (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 249.71 Bn 228.86 Bn 4.88 Bn
2 Abbott Laboratories 171.00 Bn 142.08 Bn 7.27 Bn
3 Danaher 155.79 Bn 139.61 Bn 3.61 Bn
4 Intuitive Surgical 143.91 Bn 123.46 Bn 1.96 Bn
5 Medtronic 110.42 Bn 76.29 Bn 6.34 Bn
6 Stryker 105.71 Bn 91.82 Bn 4.50 Bn
7 Boston Scientific 63.26 Bn 58.27 Bn 3.85 Bn
8 Edwards Lifesciences 49.80 Bn 33.91 Bn 1.35 Bn
9 Becton Dickinson 48.78 Bn 45.93 Bn 2.32 Bn
10 Nexalin Technology 3.09 Mn -8.70 Mn 8,897.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 130,000.00
API Access

Nexalin Technology Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NXL&period=max&api_key=YOUR_API_KEY